Porchet H C, Dayer P
Department of Medicine, University Hospital, Geneva, Switzerland.
Clin Pharmacol Ther. 1990 Aug;48(2):155-60. doi: 10.1038/clpt.1990.130.
The dihydropyridine calcium antagonist (+/-)-nicardipine shares some of the pharmacologic properties of the dihydropyridine prototype nifedipine. To compare them, serum concentrations and cardiovascular effects of 10 mg nifedipine and 20 mg (+/-)-nicardipine were evaluated at 1, 2, and 3 hours after oral intake in a randomized, crossover, single-blind study involving 79 healthy volunteers. (+/-)-Nicardipine serum concentrations were much lower than those of nifedipine, indicating a greater hepatic first-pass metabolism of (+/-)-nicardipine. There was a significant correlation between serum concentrations of both drugs. The frequency distributions of nifedipine and (+/-)-nicardipine AUC (0-3), heart rate increase, and mean arterial pressure decrease showed no bimodality. This does not confirm the proposed polymorphism of nifedipine oxidation. Concentration-effect plots indicate that (+/-)-nicardipine is more potent than nifedipine but shows comparable efficacy in blood pressure reduction.
二氢吡啶类钙拮抗剂(±)-尼卡地平具有二氢吡啶类原型药物硝苯地平的一些药理特性。为了对它们进行比较,在一项涉及79名健康志愿者的随机、交叉、单盲研究中,评估了口服10毫克硝苯地平和20毫克(±)-尼卡地平后1、2和3小时的血清浓度及心血管效应。(±)-尼卡地平的血清浓度远低于硝苯地平,表明(±)-尼卡地平的肝脏首过代谢更强。两种药物的血清浓度之间存在显著相关性。硝苯地平和(±)-尼卡地平的AUC(0 - 3)、心率增加和平均动脉压降低的频率分布均未显示双峰性。这并未证实所提出的硝苯地平氧化多态性。浓度-效应图表明,(±)-尼卡地平比硝苯地平更有效,但在降低血压方面显示出相当的疗效。